UES

MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy

BOTHELL, WA – June 25 – MediQuest Therapeutics,Inc., a specialty pharmaceutical company focused on developingtherapies for inflammatory and infectious diseases, today announcedthe completion of its confirmatory phase III study of Vascana– a topical formulation designed to treat Raynaud’sDisease. The study met its primary end point and demonstrated statistica...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase ActivationSciences, Inc. (T.A. Sciences) recently announced the results ofthe Pivotal 2005 Anti-Aging Trial of TA-65, the first human trialever to show demonstrated, measurable and positive anti-agingbenefits from a Telomerase Activator. Statistically significantresults were found in those taking TA-65 across several keyconditions of agi...

Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study

Golimumab Demonstrated Sustained Improvement in Signs andSymptoms Of Moderate to Severe Rheumatoid Arthritis With One-Thirdof Patients Achieving Disease Remission at One-YearMark BARCELONA, Spain, 14 June 2007 – One-year data show nearly75 percent of patients with moderate to severe rheumatoid arthritis(RA) receiving golimumab (CNTO 148) and methotrexate (MTX)experienced a...

To Stent or Not: Is That the Question?

Reporting of COURAGE study results confused the public about theneed and benefits of angioplasty PORTLAND, Ore., June 07, 2007 /PRNewswire/ -- The onslaught ofanti-stent news reports over the past few months has shaped thepublic's view that angioplasty doesn't work and its use shoulddecrease. Confused by the media coverage, patients have extensivelyquestioned their cardiologists about the...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

FDA Issues Safety Alert on Avandia

ROCKVILLE, Md., May 21, 2007-The U.S. Food and Drug Administration(FDA) is aware of a potential safety issue related to Avandia(rosiglitazone), a drug approved to treat type 2 diabetes. Safetydata from controlled clinical trials have shown that there is apotentially significant increase in the risk of heart attack andheart-related deaths in patients taking Avandia. However, otherpublished a...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTechInc. ("Quest" or the "Company") Quest is pleased to provide anupdate on the pre-clinical development of SL052 for the treatmentof prostate cancer. Prostate cancer is the second leading cause of cancer death inAmerican men with approximately 230,000 new cases and 30,000 deathspe...

VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting

BASKING RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --VioQuest Pharmaceuticals, Inc. , a New Jersey-basedbiopharmaceutical company focused on acquiring, developing andcommercializing targeted cancer compounds, announced data from itspreclinical studies of VQD- 002, a direct inhibitor of Aktactivation for the treatment of solid and hematologic tumors.Pre-clinical data was presented...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

Mymetics Also Announces Deal for Vaccine Delivery System NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today that the Company's HIV vaccineelicited IgA mucosal antibodies in a non-human primate model.Mucosal IgA antibodies are considered a possible first line ofdefense against infection by HIV. The data were presented bySylvain Fleury, Ph.D., My...

Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents

LANSING, Mich., March 27, 2007 /PRNewswire/ -- AfidTherapeutics, Inc. announced that it received positive results onthe ability of its new triple mode viral sequestration agents toblock viral infections of mammalian cells. The audited results wereobtained from a specialized, independent third party testingorganization. The new viral sequestrating agents are designed tobind and inactivate...